Abstract
Background Japan started vaccinations for COVID-19 in late February, 2021, mainly using BNT162b2 mRNA COVID-19 Vaccine.
Object We evaluated COVID-19 vaccination effects on infectiousness in Japan. Method: The effective reproduction number R(t) was regressed on vaccine coverage along with data of temperature, humidity, mobility, and countermeasures. We presumed two definitions for vaccine coverage: at least a single dose with a 12-day delay and a second dose. The study period was February, 2020 through May 16, 2021.
Results Estimation results indicate that vaccine coverage significantly and drastically reduced R(t) for both definitions. Results imply that increased first shot coverage by 1% point decreased R(t) by 0.5 with a 12 day delay. Moreover, increased second shot coverage by 1% point, decreased R(t) by 1 immediately.
Discussion and Conclusion Vaccination effects might be stronger because the periods when vaccination was started and rapid spread coincide with a decreasing phase of R(t).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All information used for this study has been published. There is therefore no ethical issue related to this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
ICMJE Statement Contributors JK was responsible for the coordination of the study and responsible for the data setting. YO developed the model and TS illustrated the results. All authors contributed to the writing of the final manuscript.
Data Availability
Japan Ministry of Health, Labour and Welfare. Press Releases.(in Japanese)
